Single-Cell Multi-Omics Analysis of IASO Bio's Equecabtagene Autoleucel in the Treatment of Autoimmune Diseases of the Central Nervous System Published in Science Immunology [Yahoo! Financ...
Cabaletta Bio, Inc. (CABA)
Company Research
Source: Yahoo! Finance
Immunology , a sub-journal of Science , published a research paper titled "Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity". This paper focuses on the single-cell multi-omics analysis of the fully human BCMA targeting autologous CAR-T cell injection (Equecabtagene Autoleucel, Eque-cel, R&D code: CT103A) in the treatment of patients with neuromyelitis optica spectrum disorder (NMOSD) . This paper described for the first time in the world the dynamic evolutionary trajectories of CAR-T cells in patients with autoimmune diseases, analyzed the molecular characteristics of central infiltration of CAR-T cells, revealed the mechanism of immune remodeling in the central nervous system during CAR-T therapy for autoimmune diseases of the central nervous system, and elucidated the molecular differences of CAR-T cells between patients with autoimmune diseases and cancers at the cellular and molecular levels. In 2022, IASO Bio published th
Show less
Read more
Impact Snapshot
Event Time:
CABA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CABA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CABA alerts
High impacting Cabaletta Bio, Inc. news events
Weekly update
A roundup of the hottest topics
CABA
News
- We Think Cabaletta Bio (NASDAQ:CABA) Can Afford To Drive Business Growth [Yahoo! Finance]Yahoo! Finance
- Cabaletta Bio, Inc. (NASDAQ: CABA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQGlobeNewswire
CABA
Earnings
- 5/15/24 - Miss
CABA
Sec Filings
- 5/15/24 - Form 10-Q
- 5/15/24 - Form 8-K
- 4/23/24 - Form ARS
- CABA's page on the SEC website